Crinetics Pharmaceuticals Inc.
Jeff Knight Resigns as Chief Development and Operating Officer
Summary
Crinetics Pharmaceuticals, Inc. announced that Jeff Knight, its Chief Development and Operating Officer, has resigned effective April 10, 2026. Following his resignation, Mr. Knight has entered into an Independent Consultant Agreement with the Company, under which he will provide certain services for a period of one year, renewable for an additional six months. Mr. Knight will receive compensation of $400 per hour for up to 20 hours per month, along with reimbursement for travel and out-of-pocket expenses. His unvested restricted stock units and stock options will be forfeited, while his vested stock options will remain exercisable for three months after the consulting period ends or until the period is terminated for cause. The agreement also includes a general release of claims and an extension of certain indemnification rights.
Profitelligence Alerts
Get alerts for CRNX
Be first to know when Crinetics Pharmaceuticals Inc. files with the SEC.
Filing Categories
Advertisement
About Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development of novel therapeutics for patients with endocrine conditions and other rare diseases. The primary focus of Crinetics is on crafting oral therapies that target hormone receptors, offering significant potential to transform the treatment landscape for several disorders. The company's pipeline includes investigational drugs such as paltusotine and CRN04894, aimed at addressing conditions like acromegaly and congenital adrenal hyperplasia, respectively. Crinetics combines cutting-edge drug discovery with an in-depth understanding of disease biology to impact the field of endocrinology substantially. By specializing in small molecules, Crinetics Pharmaceuticals seeks to provide new treatment options that enhance patient quality of life and address significant unmet medical needs. Headquartered in San Diego, California, the enterprise collaborates with academic institutions and industry partners to position its innovations at the forefront of medical advancement. Its work holds significant potential to influence the pharmaceutical industry, contributing to the expansion of targeted therapies within niche markets where few options currently exist.
Official SEC Documents
Advertisement